Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000378:metabolism*; D006801:Humans; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D011092:Polyethylene Glycols; D001215:Asparaginase